Dermatology M&A Activity Remains Strong Amid Broader Healthcare Decline
The dermatology industry continued to see steady add-on transactions in the first half of 2026, even as broader healthcare deal activity declined by 16% year over year. TUSK Practice Sales reported that buyer demand is focused on high-quality practices with diversified service offerings and EBITDA exceeding $500K. A recapitalization wave is underway, with at least 25 private equity-backed dermatology platforms held for five or more years now seeking new capital infusions. New state laws are also influencing the market by reducing regulatory barriers to corporate practice ownership in states like Oregon and California. This trend has shifted buyer interest toward regions with fewer restrictions on such arrangements, increasing competition among well-funded buyers looking to expand existing dermatology platforms through add-on acquisitions rather than building new ones from scratch.
Topics: dermatology healthcare M&A activity private equity regulatory changes